INTRODUCTION: Interleukin-1 beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha) are potentially important in Chronic Obstructive Pulmonary Disease (COPD), but little is known of the relationships between these cytokines and their antagonists in disease compared with healthy controls. It is unclear if concentrations relate to disease severity. The study aimed to investigate these relationships and to assess the potential activity of each cytokine in the context of their antagonists. METHODS: Plasma cytokines, soluble receptors, and cell counts were measured in patients with stable COPD and age-matched healthy controls (n = 15 for both) daily for 5 days; these mediators were also measured in corresponding sputum samples from the COPD patients. RESULTS: COPD patients had significantly reduced concentrations of the antagonists, IL-1sRII, and IL-1RA compared with controls. In COPD, IL-1beta exceeded its antagonists and correlated significantly with BMI and FEV1, while plasma IL-1RA correlated positively with BMI but negatively with sputum IL-1beta, neutrophil, and macrophage counts and smoking history. TNFalpha antagonists exceeded agonists in both groups and did not correlate with COPD severity. CONCLUSIONS: Endogenous IL-1beta antagonists appear reduced in COPD. Furthermore, IL-1beta correlated with clinical aspects of disease severity, suggesting that IL-1beta may play a critical role in COPD. Given the relevant concentrations and binding affinities, it is likely that TNFalpha has limited activity in stable COPD.
INTRODUCTION:Interleukin-1 beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha) are potentially important in Chronic Obstructive Pulmonary Disease (COPD), but little is known of the relationships between these cytokines and their antagonists in disease compared with healthy controls. It is unclear if concentrations relate to disease severity. The study aimed to investigate these relationships and to assess the potential activity of each cytokine in the context of their antagonists. METHODS: Plasma cytokines, soluble receptors, and cell counts were measured in patients with stable COPD and age-matched healthy controls (n = 15 for both) daily for 5 days; these mediators were also measured in corresponding sputum samples from the COPD patients. RESULTS: COPD patients had significantly reduced concentrations of the antagonists, IL-1sRII, and IL-1RA compared with controls. In COPD, IL-1beta exceeded its antagonists and correlated significantly with BMI and FEV1, while plasma IL-1RA correlated positively with BMI but negatively with sputum IL-1beta, neutrophil, and macrophage counts and smoking history. TNFalpha antagonists exceeded agonists in both groups and did not correlate with COPD severity. CONCLUSIONS: Endogenous IL-1beta antagonists appear reduced in COPD. Furthermore, IL-1beta correlated with clinical aspects of disease severity, suggesting that IL-1beta may play a critical role in COPD. Given the relevant concentrations and binding affinities, it is likely that TNFalpha has limited activity in stable COPD.
Authors: Stephen I Rennard; Charles Fogarty; Steven Kelsen; William Long; Joe Ramsdell; James Allison; Donald Mahler; Constantine Saadeh; Thomas Siler; Phillip Snell; Phillip Korenblat; William Smith; Mitchell Kaye; Michael Mandel; Charles Andrews; Rachakonda Prabhu; James F Donohue; Rosemary Watt; Kim Hung Lo; Rozsa Schlenker-Herceg; Elliot S Barnathan; John Murray Journal: Am J Respir Crit Care Med Date: 2007-02-08 Impact factor: 21.405
Authors: A A Eid; A A Ionescu; L S Nixon; V Lewis-Jenkins; S B Matthews; T L Griffiths; D J Shale Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405
Authors: Hideya Kitamura; Stephanie Cambier; Sangeeta Somanath; Tyren Barker; Shunsuke Minagawa; Jennifer Markovics; Amanda Goodsell; Jean Publicover; Louis Reichardt; David Jablons; Paul Wolters; Arthur Hill; James D Marks; Jianlong Lou; Jean-Francois Pittet; Jack Gauldie; Jody Lynn Baron; Stephen L Nishimura Journal: J Clin Invest Date: 2011-06-06 Impact factor: 14.808
Authors: M G Adas-Okuma; S S Maeda; M R Gazzotti; C M Roco; C O Pradella; O A Nascimento; E F Porto; J G H Vieira; J R Jardim; M Lazaretti-Castro Journal: Osteoporos Int Date: 2019-12-06 Impact factor: 4.507
Authors: Oliver J Brand; Sangeeta Somanath; Catherine Moermans; Haruhiko Yanagisawa; Mitsuo Hashimoto; Stephanie Cambier; Jennifer Markovics; Andrew J Bondesson; Arthur Hill; David Jablons; Paul Wolters; Jianlong Lou; James D Marks; Jody L Baron; Stephen L Nishimura Journal: J Biol Chem Date: 2015-04-27 Impact factor: 5.157
Authors: Wei Li; Jennifer S Moylan; Melissa A Chambers; Jeffrey Smith; Michael B Reid Journal: Am J Physiol Cell Physiol Date: 2009-07-22 Impact factor: 4.249
Authors: Shunsuke Minagawa; Jianlong Lou; Robert I Seed; Anthony Cormier; Shenping Wu; Yifan Cheng; Lynne Murray; Ping Tsui; Jane Connor; Ronald Herbst; Cedric Govaerts; Tyren Barker; Stephanie Cambier; Haruhiko Yanagisawa; Amanda Goodsell; Mitsuo Hashimoto; Oliver J Brand; Ran Cheng; Royce Ma; Kate J McKnelly; Weihua Wen; Arthur Hill; David Jablons; Paul Wolters; Hideya Kitamura; Jun Araya; Andrea J Barczak; David J Erle; Louis F Reichardt; James D Marks; Jody L Baron; Stephen L Nishimura Journal: Sci Transl Med Date: 2014-06-18 Impact factor: 17.956
Authors: Nazia Chaudhuri; Hannah Jary; Simon Lea; Naimat Khan; Katie C Piddock; David H Dockrell; Ken Donaldson; Rodger Duffin; Dave Singh; Lisa C Parker; Ian Sabroe Journal: PLoS One Date: 2012-12-07 Impact factor: 3.240
Authors: Juan P de-Torres; David Blanco; Ana B Alcaide; Luis M Seijo; Gorka Bastarrika; María José Pajares; Arrate Muñoz-Barrutia; Carlos Ortiz-de-Solorzano; Ruben Pio; Arantza Campo; Usua Montes; Victor Segura; Jesús Pueyo; Luis M Montuenga; Javier J Zulueta Journal: PLoS One Date: 2013-04-05 Impact factor: 3.240